Aggarwal RR, Vuky J, VanderWeele D, Rettig M, et al. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989.
PMID: 40138611